Interpace Diagnostics Supports Research Efforts of Pancreatic and Thyroid Cancer Patient Advocacy Groups
September 17 2018 - 8:30AM
Interpace Employees Participate in Local Events
in Support of Lustgarten Foundation for Pancreatic Cancer Research,
Thyroid, Head and Neck Cancer Foundation, and Pancreatic Cancer
Action Network
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace”
or “the Company”), a fully integrated commercial and bioinformatics
company that provides beneficial molecular diagnostic tests and
pathology services that improve patient diagnosis and management,
announced today that the Company will participate in several local
events in support of the following patient advocacy groups:
Lustgarten Foundation Pancreatic Cancer Research (The Lustgarten
Foundation), Thyroid, Head and Neck Cancer (THANC) Foundation, and
Pancreatic Cancer Action Network (PanCAN).
The Lustgarten Foundation and PanCAN are global organizations
striving to advance scientific and medical research for pancreatic
cancer in order to improve the lives of patients and their
families. In their fight against one of the world’s deadliest
cancers, the organizations provide funding for research as well as
patient services, advocacy and community engagement. To
support these organizations, Interpace employees will participate
in the following events:
- Lustgarten Foundation Pancreatic
Cancer Research Walk on September 23,
2018
- PanCAN Purple Stride Run/Walk on
October 13, 2018
The THANC Foundation is committed to supporting research and
education for the advancement of early detection and treatment of
thyroid and head and neck cancer. As one of the largest private
funders of research in the U.S. for these types of cancer, the
organization also aims to advance new therapies and improve patient
quality of life by alleviating suffering and functional impairment.
To support the THANC Foundation, Interpace employees will
participate in the THANC Foundation Charitable Outing on September
24, 2018.
“At Interpace, we operate everyday with the intent of advancing
patient care through molecular diagnostic testing, which can allow
for earlier and more accurate diagnosis of grievous diseases such
as pancreatic and thyroid cancer,” said Jack Stover, CEO of
Interpace. “To further these efforts, the Interpace community is
excited to be part of local events hosted by PanCAN, the Lustgarten
Foundation, and the THANC Foundation organizations that share our
focus of serving and making a meaningful impact on lives of
patients and their families.”
About the Pancreatic Cancer Action Network
(PanCAN) The Pancreatic Cancer Action Network (PanCAN) is
accelerating the pace of research progress for one of the world’s
deadliest cancers. With an urgent mission to improve outcomes
for pancreatic cancer patients and double survival by 2020, the
organization, founded in 1999, executes a bold and comprehensive
strategy to Wage Hope through research, patient services, advocacy
and community engagement. The organization’s visionary goals,
world-class programs and services, extensive grassroots network,
patient-focused outcomes and advisory board of scientific and
medical leaders, provide the critical backdrop to help pancreatic
cancer patients today and create transformational change for all
patients in the future.
About the Lustgarten Foundation
The Lustgarten Foundation is America’s largest private funder of
pancreatic cancer research. Based in Woodbury, N.Y., the Foundation
supports research to find a cure for pancreatic cancer, facilitates
dialogue within the medical and scientific community, and educates
the public about the disease through awareness campaigns and
fundraising events. Since its inception, the Lustgarten Foundation
has directed $154 million to research and assembled the best
scientific minds with the hope that one day, a cure can be found.
Thanks to separate funding to support administrative expenses, 100
percent of every dollar donated to the Foundation goes directly to
pancreatic cancer research. For more information, please visit
www.lustgarten.org.
About the Thyroid, Head and Neck Cancer (THANC)
FoundationThe Thyroid, Head and Neck Cancer (THANC)
Foundation was incorporated in 2003 and quickly became the largest
private funder of research in the United States for these types of
cancer. THANC is committed to supporting research and education in
the early detection and treatment of thyroid and head and neck
cancer, to advancing new therapies, and to alleviating the
suffering and functional impairment of patients who undergo
treatment.
About Interpace Diagnostics Group,
Inc.Interpace is a fully integrated commercial and
bioinformatics company that provides clinically useful molecular
and related first line diagnostic tests and pathology services for
evaluating risk of cancer by leveraging the latest technology in
personalized medicine for improved patient diagnosis and
management. The Company currently has four commercialized molecular
tests and one test in a clinical evaluation process (CEP);
PancraGEN® for the diagnosis and prognosis of pancreatic cancer
from pancreatic cysts; ThyGenX® (currently ThyGeNEXT™) for the
diagnosis of thyroid cancer from thyroid nodules utilizing a next
generation sequencing assay; ThyraMIR® for the diagnosis of thyroid
cancer from thyroid nodules utilizing a proprietary gene expression
assay; and RespriDx™, that differentiates lung cancer of primary
vs. metastatic origin. BarreGEN®, for Barrett's Esophagus, is
currently being “soft launched” with key opinion leaders as we
continue to gather data on this assay that will assist us in
seeking favorable reimbursement as well as important clinical
information. Barrett's Esophagus is a rapidly growing diagnosis
that affects over three million people in the US, and over time can
progress to esophageal cancer. The Company’s data base includes
data from over 45,000 patients who have been tested using the
Company’s current products, including over 15,000 molecular tests
for thyroid nodules. Interpace has been designated by CIO
Applications magazine as one of the top 20 companies for providing
bioinformatics solutions. Interpace’s mission is to provide
personalized medicine through molecular diagnostics, innovation and
data to advance patient care based on rigorous science. For more
information, please visit Interpace’s website at
www.interpacediagnostics.com
Forward Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934 and the Private Securities Litigation Reform
Act of 1995, relating to the Company's future financial and
operating performance, competitive and market conditions and future
business decisions, all of which are difficult or impossible to
predict accurately and many of which are beyond the Company's
control. These statements also involve known and unknown risks,
uncertainties and other factors that may cause the Company's actual
results to be materially different from those expressed or implied
by any forward-looking statement. Known and unknown risks,
uncertainties and other factors include, but are not limited to,
the Company’s history of losses, the Company's ability to
adequately finance the business, the market's acceptance of its
molecular diagnostic tests, its ability to retain or secure
reimbursement, its ability to secure additional business and
generate higher profit margins through sales of its molecular
diagnostic tests, in-licensing or other means, projections of
future revenues, growth, gross profit and anticipated internal rate
of return on investments and its ability to maintain its NASDAQ
listing. Additionally, all forward-looking statements are subject
to the “Risk Factors” detailed from time to time in the Company's
SEC filings, including its Annual Report on Form 10-K for the
fiscal year ended December 31, 2017, filed on March 23, 2018,
Quarterly Reports on Form 10-Q and other SEC filings. Because of
these and other risks, uncertainties and assumptions, undue
reliance should not be placed on these forward-looking statements.
In addition, these statements speak only as of the date of this
press release and, except as may be required by law, the Company
undertakes no obligation to revise or update publicly any
forward-looking statements for any reason.
CONTACTS:
Interpace Diagnostics
Investor Relations
Joseph Green / Andrew Gibson
646-653-7030 / 7719
jgreen@edisongroup.com/ agibson@edisongroup.com
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Apr 2023 to Apr 2024